BERMUDA-BUSINESS-DEVELOP
24.5.2023 16:10:33 CEST | Business Wire | Press release
Suzanne Johnson, Senior Advisor, United Nations (UN) Global Compact Ocean Stewardship Coalition, is the latest addition to the impressive list of speakers at the second annual Bermuda Climate Summit, presented by the Bermuda Business Development Agency (BDA), in partnership with KBRA.
Bermuda’s Deputy Premier, The Hon. Walter Roban, JP, MP, will open the Summit on June 26 with a conversation with Jim Nadler, President & CEO, KBRA. Another luncheon keynote will be given by Joshua Rosenberg, Chief Risk Officer, Federal Reserve Bank of New York on June 27.
Suzanne Johnson said, “It will be a pleasure to discuss the UN Global Compact work to advance a more sustainable ocean economy at the Bermuda Climate Summit. I look forward to discussing how ocean industry and finance can help to address the climate and nature crisis with financial service executives, academics and international regulators in attendance at the summit.”
David Hart, CEO, BDA said, “We are honoured to have a leading expert like Suzanne Johnson giving a keynote at our Bermuda Climate Summit joining an already impressive line-up. It is sure to be an incredible two days of informative and collaborative discussions not just about climate related challenges, but how Bermuda is the perfect place to create and deliver innovative solutions to the global marketplace.”
We are strongly encouraging prospective delegates from overseas to secure their room and receive special rates at our event hotel, the Hamilton Princess & Beach Club, by booking online prior to May 25. Click here to register – this year’s theme is: ‘Bermuda - Climate Central’.
Stay tuned to the BDA website for agenda updates– sessions confirmed to date include: Impact of a Changing Climate on Atlantic Hurricane Frequency and Severity moderated by Marla Pourrabbani, Data Scientist, Senior Manager, ESG and Sustainability, Deloitte, with panellists: Dr. Pete Dailey, Head of Research, Aeolus, Liz Henderson, Co-Head Catastrophe Analytics, Executive Managing Director, Reinsurance Solutions, Aon, Dr. Peter Sousounis, Vice President/Director Climate Change Research, Verisk, and Craig Tillman, President, RenaissanceRe Risk Sciences.
How Do You Measure Environmental Impact? will be moderated by Barclay Palmer, Executive Editor and Head of Strategy, Climate and Capital Media, and include panellists, Kevin Cei, Climate and Weather Solutions Executive, Jupiter Intelligence, Michele DeMers, CEO, Boundless Impact Research & Analytics, and Keith Pitts, SVP, Sustainability and Regulatory Strategy, Bioceres Crop Solutions.
What’s Ahead in the United States? will be moderated by John Huff, President & CEO, Association of Bermuda Insurers and Reinsurers (ABIR) and include panellists, Ricardo Lara, Insurance Commissioner, California Department of Insurance, Co-Chair of the NAIC Climate and Resiliency Task Force and Lori Wing-Heier, Director, Alaska Division of Insurance, Co-Chair of the NAIC Climate and Resiliency Task Force.
ESG: Where Does the Road Go From Here? will be moderated by Victoria Harman, Founder and Principal, VL Harmon Advisors, and will include panellists, Prabh Banga, VP Sustainability, Aecon, Harry Masters, Director, Advancing Green, Caroline McGill, Principal, Sustainability, and Impact Investment Strategy, Hillbreak and Patrick Welch, Chief ESG and Ratings Policy Officer, KBRA.
Green Opportunities, an Investor’s Perspective will be moderated by Bill Cox, Global Head of Corporate, Financial and Government Ratings, KBRA, with panellists Alexandra Cooley, Chief Investment Officer, Nuveen, Andrea Griffin, Global Head of Responsible Investments Specialists, HSBC Asset Management and Steve Hatfield, US Head of ESG, Carlyle Group.
Global Climate Risk will be moderated by Jeane Nikolai, Director of Energy, Government of Bermuda, and will include panellists Dr. Mark Guishard, Chartered Meteorologist, Adjunct Scientist and Trustee, BIOS, Dr. Raveem Ismail, Head of Parametric Underwriting, Africa Specialty Risks (ASR Re) and Dr. Simon Young, Senior Director, Willis Towers Watson.
Biodiversity: Our Strongest Natural Defense Against Climate Change will be moderated by Slav Gatchev, Managing Director, Sustainable Debt, The Nature Conservancy, with panellists, Osho Jha, CEO & Co-Founder at dClimate, Co-Founder & Chief Data Scientist at Arbol Inc, James Kench, Head of Insurance, KITA, and Natalia Moudrak, Climate Resiliency Leader, AON.
Climate and the Evolving Regulatory and Reporting Landscape will be moderated by Suzanne Williams-Charles, Director of Policy and Regulation, Corporate Secretary and Data Privacy Officer, ABIR, and feature panellists Ralf Kuerzdoerfer, Deputy Director, Supervision (Insurance), Bermuda Monetary Authority, Sohini Chowdhury, Senior Director, Moody’s Analytics, Ricardo Lara, Insurance Commissioner, California Department of Insurance and Arnaud van Dijk, Partner, ESG, KPMG.
The U.S. Federal Flood Programme and the (Re)Insurance Sector, will be moderated by Peter Giacone, Global Head of Insurance, KBRA and include panelists, Chris Brown – Partner, Mindset, Chlora Lindley-Myers, NAIC President and Director of the Missouri Department of Commerce and Insurance, and Andy Neal, Managing Director, Public Private Partnerships, Aon.
Net Zero? will be moderated by Miqdaad Versi, Head of ESG, Oxbow Partners, UK, and feature panelists Rachael Dalheise. Head of Sustainability, Convex, Andrew MacFarlane, Head of Climate, AXA XL, a Division of AXA, Andrew Smith, Chief Risk and Sustainability Officer, Conduit Re and Dr. Steve Smith- Head of Research & Development, Vantage.
The Power of Partnerships, which will be moderated by Jeff Manson, SVP Underwriting and Head of Global Public Sector Partnership, Renaissance Re Ltd, and will include panellists, Ekhosuehi Iyahen, Secretary General, Insurance Development Forum, Sid Miller, Director, Climate Wise, Rebekah Clement, Head of Sustainability, Lloyds, and Chair of SMI Climate Action Committee, and Tim Nielander, Founder and President, GP3 Institute.
Deep Ocean Solutions will be moderated by William Curry, President and CEO, BIOS, and feature panelists Neil Eckert, Executive Chairman, Conduit Re, Irene Polnyi- Additional Ventures Affiliate, and Mallory Ringham, PhD Chemical Oceanography, Ebb Carbon.
The BDA is grateful for the continued support of our headline sponsor KBRA, as well as: diamond sponsor Conduit Re; platinum sponsor Aon; gold sponsors Deloitte, Fidelis and Hub Culture; and silver sponsors Aeolus, Aspen, AXA XL, Belco, and KPMG. Our supporting sponsors are Butterfield and HSBC. Our media partners are The Insurer, Insurance Insider and Bermuda:Re+ILS. Our spirits partner is Goslings. Other sponsorship opportunities are still available; please e-mail bermudaclimate@bda.bm if you wish to participate.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005581/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
